Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

17.45USD
19 Apr 2018
Change (% chg)

$0.15 (+0.87%)
Prev Close
$17.30
Open
$17.25
Day's High
$17.50
Day's Low
$17.25
Volume
4,797
Avg. Vol
90,095
52-wk High
$18.75
52-wk Low
$7.30

Select another date:

Fri, Mar 16 2018

Stemline Therapeutics wins dismissal of shareholder lawsuit

A federal judge has dismissed a lawsuit accusing Stemline Therapeutics Inc of misleading investors about its ability to address the risk of a fatal side effect associated with a drug it was developing to treat certain blood-related cancers.

BRIEF-Stemline Therapeutics Inc - Co Launched An At-Market Offering Of Up To $50 Million Worth Of Shares

* STEMLINE THERAPEUTICS INC - ‍ON MARCH 16, 2018, CO LAUNCHED AN AT--MARKET OFFERING OF UP TO $50 MILLION WORTH OF SHARES OF COMPANY'S COMMON STOCK​ Source text (http://bit.ly/2HHHaYN) Further company coverage: (Reuters.Brief@thomsonreuters.com)

BRIEF-Stemline Therapeutics Q4 Loss Per Share $0.93

* STEMLINE THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS

BRIEF-Stemline Therapeutics Prices $51.8 Mln Public Offering

* STEMLINE THERAPEUTICS PRICES $51.8 MILLION PUBLIC OFFERING OF COMMON STOCK

BRIEF-Stemline Therapeutics Announces Proposed Public Offering Of Common Stock

* STEMLINE THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Stemline Therapeutics reports Q3 loss per share $0.68

* Stemline Therapeutics reports third quarter 2017 financial results

BRIEF-Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​

* Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​

Select another date: